Memantine

Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.

Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.

Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.

Dufite inganda nyinshi zo mu rwego rwo hejuru hamwe nubufatanye bwimbitse, zishobora kuguha ibicuruzwa byiza kandi nibiciro byapiganwa. Turashobora kandi gutanga kugabanyirizwa kugura byinshi.Kandi turafatanya namasosiyete menshi yohereza ibicuruzwa byumwuga, birashobora gutanga ibicuruzwa neza kandi neza mumaboko yawe. Igihe cyo gutanga ni iminsi 3-20 nyuma yo kwemeza ko wishyuye.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003. It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other. 

1. Waba uruganda cyangwa isosiyete yubucuruzi?
Turi compnay ihuza inganda nubucuruzi, dutanga serivise imwe.OEM irashobora kwemerwa.

2. Utanga ingero? Nubuntu cyangwa birenze?
Ingero z'ubuntu. Amafaranga yo gutwara ibicuruzwa agomba kwishyurwa kuruhande rwawe.

3. Waba ufite ibyemezo bijyanye no kugenzura ubuziranenge?
Icyemezo cya ISO 9001: 2008 kugirango cyemeze ubuziranenge.

4. Niki nakagombye gutanga kugirango mbone amagambo?
Pls utumenyeshe ubwoko bwibicuruzwa ukeneye, gutondekanya ingano, aderesi hamwe nibisabwa byihariye. Amagambo azakorwa kugirango ubone igihe.

5. Ni ubuhe buryo bwo kwishyura ukunda? Ni ayahe magambo yemewe?
Amasezerano yo gutanga yemewe: FOB, CFR, CIF, EXW;
Amafaranga yemewe yo kwishyura: USD;
Ubwoko bwo Kwishura Bwemewe: T / T, Western Union; Paypal, Ubwishingizi bw'Ubucuruzi.
Ururimi ruvugwa: Icyongereza.